Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec, a biopharmaceutical company, has extended its research collaboration and license agreement with Novartis.
Subscribe to our email newsletter
As per the extension, Novartis will fund research at GenVec through January 2013 to support its hearing loss and balance disorders program.
GenVec has entered into a worldwide licensing and collaboration agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders, in January 2010.
In August 2010, GenVec entered into an additional agreement with Novartis, to manufacture clinical trial material for up to two lead product candidates for this program.
GenVec research vice president Douglas Brough said GenVec has worked closely with Novartis for the past two years to move the program forward.
"This extension will allow GenVec to continue supporting this important effort," Brough added.